Allurion Technologies, Inc. reported a significant decline in financial performance for the third quarter of 2025, with revenues of $2.7 million, a 50% decrease from $5.4 million in the same period last year. For the nine months ending September 30, 2025, total revenue was $11.6 million, down 56% from $26.5 million in 2024. The company attributed this decline to distributor transitions, reduced investment in sales and marketing, and a temporary suspension of sales in France. The gross profit also fell sharply, totaling $1.3 million for the quarter and $8.0 million for the nine months, reflecting a similar percentage decrease.
Operating expenses decreased to $10.9 million for the third quarter, down from $15.5 million in 2024, and $31.8 million for the nine months, compared to $52.1 million in the previous year. The reductions were primarily due to lower sales and marketing expenses, which fell by 40% to $3.1 million in the third quarter, and a 37% decrease in research and development costs. Despite these reductions, the company reported a net loss of $11.9 million for the quarter, compared to a net income of $8.7 million in the prior year, and a net loss of $22.7 million for the nine months, contrasting with a net income of $2.4 million in 2024.
Allurion has undergone strategic restructuring, including a reduction in workforce by approximately 65%, aimed at focusing on low-dose GLP-1 combination therapy and U.S. market entry. The company has also launched several initiatives to enhance its research and development pipeline and improve its sales strategy. As of September 30, 2025, Allurion had cash and cash equivalents of $6.1 million, down from $15.4 million at the end of 2024, and an accumulated deficit of $244.9 million.
Looking ahead, Allurion anticipates continued operating losses as it seeks to obtain regulatory approvals for its products and refine its marketing strategies. The company has indicated that it will need to raise additional capital to fund its operations, which may include equity offerings or debt financing. The ongoing challenges in achieving profitability and the need for further funding raise concerns about the company's ability to sustain operations in the long term. Allurion's stock is currently traded on the New York Stock Exchange under the ticker symbol "ALUR."
About ALLURION TECHNOLOGIES, INC.
Allurion Technologies, Inc. is a medical device company focused on combating obesity through its innovative Allurion Program, which features the swallowable, Procedureless™ intragastric balloon for weight loss. Targeting the $54 billion global obesity treatment market, Allurion aims to serve over 10 million potential U.S. patients. The company enhances patient outcomes with AI-powered remote monitoring and behavior change tools, while expanding its offerings to include weight loss medications and combination therapies.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.